Berry Genomics Co.,Ltd Logo

Berry Genomics Co.,Ltd

000710.SZ

(0.8)
Stock Price

9,14 CNY

-11.57% ROA

-16.6% ROE

-10.29x PER

Market Cap.

3.323.097.400,00 CNY

10.43% DER

0% Yield

-28.38% NPM

Berry Genomics Co.,Ltd Stock Analysis

Berry Genomics Co.,Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Berry Genomics Co.,Ltd Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (16%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.69x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 ROE

The stock's ROE indicates a negative return (-16.65%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-12.48%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-27) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Berry Genomics Co.,Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Berry Genomics Co.,Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Berry Genomics Co.,Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Berry Genomics Co.,Ltd Revenue
Year Revenue Growth
1994 76.186.118
1995 107.080.571 28.85%
1996 112.801.215 5.07%
1997 113.053.607 0.22%
1998 118.427.982 4.54%
1999 99.772.105 -18.7%
2000 79.278.310 -25.85%
2001 51.132.768 -55.04%
2002 62.619.977 18.34%
2003 81.317.010 22.99%
2004 119.662.111 32.04%
2005 130.579.949 8.36%
2006 148.658.025 12.16%
2007 180.608.401 17.69%
2008 286.852.054 37.04%
2009 408.956.180 29.86%
2010 464.161.241 11.89%
2011 409.661.686 -13.3%
2012 331.077.628 -23.74%
2013 262.234.824 -26.25%
2014 273.643.289 4.17%
2015 230.056.809 -18.95%
2016 247.380.252 7%
2017 1.171.191.341 78.88%
2018 1.439.789.044 18.66%
2019 1.617.641.301 10.99%
2020 1.540.385.732 -5.02%
2021 1.422.180.921 -8.31%
2022 1.368.007.211 -3.96%
2023 1.219.639.132 -12.16%
2023 1.151.416.785 -5.93%
2024 1.076.869.632 -6.92%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Berry Genomics Co.,Ltd Research and Development Expenses
Year Research and Development Expenses Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 983.672 100%
2011 1.264.065 22.18%
2012 1.459.048 13.36%
2013 1.920.890 24.04%
2014 2.063.585 6.91%
2015 5.806.348 64.46%
2016 3.920.654 -48.1%
2017 33.558.469 88.32%
2018 91.279.260 63.24%
2019 119.502.996 23.62%
2020 125.796.137 5%
2021 128.228.933 1.9%
2022 106.735.118 -20.14%
2023 99.244.261 -7.55%
2023 110.010.752 9.79%
2024 69.538.688 -58.2%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Berry Genomics Co.,Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
1994 7.527.282
1995 11.552.559 34.84%
1996 11.055.637 -4.49%
1997 10.693.319 -3.39%
1998 9.904.745 -7.96%
1999 8.743.314 -13.28%
2000 12.133.462 27.94%
2001 28.619.113 57.6%
2002 45.505.089 37.11%
2003 10.438.823 -335.92%
2004 13.525.283 22.82%
2005 20.437.539 33.82%
2006 13.874.183 -47.31%
2007 12.306.767 -12.74%
2008 16.346.108 24.71%
2009 22.961.966 28.81%
2010 14.251.973 -61.11%
2011 10.312.505 -38.2%
2012 10.929.300 5.64%
2013 9.785.802 -11.69%
2014 14.809.155 33.92%
2015 14.611.667 -1.35%
2016 9.637.168 -51.62%
2017 38.387.794 74.9%
2018 29.108.883 -31.88%
2019 29.973.129 2.88%
2020 31.731.233 5.54%
2021 28.475.049 -11.44%
2022 23.619.104 -20.56%
2023 408.773.500 94.22%
2023 27.014.276 -1413.18%
2024 -26.020.197 203.82%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Berry Genomics Co.,Ltd EBITDA
Year EBITDA Growth
1994 17.864.017
1995 22.135.901 19.3%
1996 22.594.826 2.03%
1997 25.213.918 10.39%
1998 31.660.700 20.36%
1999 19.807.857 -59.84%
2000 13.605.971 -45.58%
2001 -28.699.757 147.41%
2002 -31.291.181 8.28%
2003 20.098.996 255.69%
2004 15.827.275 -26.99%
2005 -58.926 26959.58%
2006 14.359.204 100.41%
2007 3.634.561 -295.07%
2008 17.811.318 79.59%
2009 29.881.423 40.39%
2010 21.895.700 -36.47%
2011 13.615.344 -60.82%
2012 11.529.529 -18.09%
2013 12.298.338 6.25%
2014 23.731.254 48.18%
2015 -1.581.401 1600.65%
2016 55.148.233 102.87%
2017 345.244.247 84.03%
2018 391.750.381 11.87%
2019 546.477.732 28.31%
2020 376.120.084 -45.29%
2021 67.572.799 -456.61%
2022 -62.245.414 208.56%
2023 339.759.159 118.32%
2023 37.346.375 -809.75%
2024 144.059.480 74.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Berry Genomics Co.,Ltd Gross Profit
Year Gross Profit Growth
1994 27.084.448
1995 36.098.466 24.97%
1996 38.044.069 5.11%
1997 40.279.800 5.55%
1998 41.091.543 1.98%
1999 27.620.988 -48.77%
2000 20.699.130 -33.44%
2001 -7.592.946 372.61%
2002 5.384.100 241.03%
2003 15.647.834 65.59%
2004 19.570.931 20.05%
2005 15.339.768 -27.58%
2006 21.274.266 27.9%
2007 13.496.853 -57.62%
2008 29.931.266 54.91%
2009 55.182.363 45.76%
2010 55.241.362 0.11%
2011 40.956.975 -34.88%
2012 41.728.244 1.85%
2013 32.808.616 -27.19%
2014 18.272.819 -79.55%
2015 8.366.698 -118.4%
2016 16.746.032 50.04%
2017 715.931.589 97.66%
2018 838.504.579 14.62%
2019 988.838.919 15.2%
2020 810.628.620 -21.98%
2021 636.207.185 -27.42%
2022 584.360.057 -8.87%
2023 592.945.680 1.45%
2023 515.195.936 -15.09%
2024 459.478.460 -12.13%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Berry Genomics Co.,Ltd Net Profit
Year Net Profit Growth
1994 12.301.678
1995 14.818.650 16.99%
1996 15.772.469 6.05%
1997 25.188.528 37.38%
1998 23.621.514 -6.63%
1999 13.750.939 -71.78%
2000 1.608.935 -754.66%
2001 -44.340.312 103.63%
2002 -50.809.556 12.73%
2003 3.174.241 1700.68%
2004 638.036 -397.5%
2005 -14.276.456 104.47%
2006 1.192.938 1296.75%
2007 -12.691.997 109.4%
2008 2.818.752 550.27%
2009 10.453.330 73.03%
2010 8.076.488 -29.43%
2011 500.761 -1512.84%
2012 392.984 -27.43%
2013 -6.156.855 106.38%
2014 6.878.248 189.51%
2015 -13.008.740 152.87%
2016 -4.185.928 -210.77%
2017 232.749.588 101.8%
2018 268.091.948 13.18%
2019 390.618.298 31.37%
2020 210.665.188 -85.42%
2021 -109.862.289 291.75%
2022 -252.249.852 56.45%
2023 -159.396.649 -58.25%
2023 -427.196.506 62.69%
2024 4.110.880 10491.85%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Berry Genomics Co.,Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1994 0
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 1 0%
2018 1 0%
2019 1 100%
2020 1 0%
2021 0 0%
2022 -1 0%
2023 0 0%
2023 -1 100%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Berry Genomics Co.,Ltd Free Cashflow
Year Free Cashflow Growth
1998 10.966.047
1999 -6.993.008 256.81%
2000 -15.200.843 54%
2001 -85.400.661 82.2%
2002 14.866.722 674.44%
2003 -2.707.142 649.17%
2004 -6.561.437 58.74%
2005 6.918.158 194.84%
2006 3.118.697 -121.83%
2007 4.331.298 28%
2008 51.899.793 91.65%
2009 -5.042.794 1129.19%
2010 70.995.662 107.1%
2011 -27.625.950 356.99%
2012 30.358.269 191%
2013 8.638.331 -251.44%
2014 16.519.773 47.71%
2015 -133.336.851 112.39%
2016 -72.100.916 -84.93%
2017 -130.482.477 44.74%
2018 -529.690 -24533.79%
2019 -172.204.191 99.69%
2020 48.762.302 453.15%
2021 -242.659.961 120.09%
2022 -52.131.338 -365.48%
2023 55.905.409 193.25%
2023 -2.066.595 2805.2%
2024 41.643.862 104.96%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Berry Genomics Co.,Ltd Operating Cashflow
Year Operating Cashflow Growth
1998 28.296.271
1999 15.300.482 -84.94%
2000 -8.214.096 286.27%
2001 -85.388.571 90.38%
2002 14.910.671 672.67%
2003 -1.228.278 1313.95%
2004 -6.425.037 80.88%
2005 7.580.398 184.76%
2006 11.677.975 35.09%
2007 4.703.248 -148.3%
2008 57.755.051 91.86%
2009 -2.328.884 2579.95%
2010 76.193.688 103.06%
2011 -21.457.858 455.09%
2012 48.265.432 144.46%
2013 15.627.955 -208.84%
2014 18.909.920 17.36%
2015 -70.809.802 126.71%
2016 -14.191.558 -398.96%
2017 74.350.103 119.09%
2018 165.331.569 55.03%
2019 123.056.710 -34.35%
2020 161.310.075 23.71%
2021 94.031.452 -71.55%
2022 21.178.809 -343.99%
2023 111.006.913 80.92%
2023 27.824.386 -298.96%
2024 55.917.125 50.24%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Berry Genomics Co.,Ltd Capital Expenditure
Year Capital Expenditure Growth
1998 17.330.224
1999 22.293.490 22.26%
2000 6.986.747 -219.08%
2001 12.090 -57689.46%
2002 43.949 72.49%
2003 1.478.864 97.03%
2004 136.400 -984.21%
2005 662.240 79.4%
2006 8.559.278 92.26%
2007 371.950 -2201.19%
2008 5.855.257 93.65%
2009 2.713.910 -115.75%
2010 5.198.025 47.79%
2011 6.168.092 15.73%
2012 17.907.163 65.56%
2013 6.989.624 -156.2%
2014 2.390.146 -192.43%
2015 62.527.050 96.18%
2016 57.909.357 -7.97%
2017 204.832.580 71.73%
2018 165.861.259 -23.5%
2019 295.260.901 43.83%
2020 112.547.772 -162.34%
2021 336.691.413 66.57%
2022 73.310.147 -359.27%
2023 55.101.504 -33.05%
2023 29.890.981 -84.34%
2024 14.273.263 -109.42%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Berry Genomics Co.,Ltd Equity
Year Equity Growth
1994 39.031.239
1995 41.147.480 5.14%
1996 73.946.101 44.35%
1997 185.584.846 60.16%
1998 211.435.540 12.23%
1999 220.904.139 4.29%
2000 207.059.227 -6.69%
2001 161.478.417 -28.23%
2002 108.872.395 -48.32%
2003 112.108.618 2.89%
2004 112.750.533 0.57%
2005 98.589.009 -14.36%
2006 99.781.948 1.2%
2007 94.505.369 -5.58%
2008 104.341.896 9.43%
2009 114.509.530 8.88%
2010 122.223.009 6.31%
2011 122.499.538 0.23%
2012 123.680.370 0.95%
2013 120.997.750 -2.22%
2014 143.079.207 15.43%
2015 131.545.835 -8.77%
2016 135.679.367 3.05%
2017 1.560.462.904 91.31%
2018 1.942.321.015 19.66%
2019 2.347.046.642 17.24%
2020 2.422.447.811 3.11%
2021 2.523.702.051 4.01%
2022 2.329.327.842 -8.34%
2023 2.199.537.939 -5.9%
2023 1.894.601.223 -16.1%
2024 1.907.578.845 0.68%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Berry Genomics Co.,Ltd Assets
Year Assets Growth
1994 100.364.723
1995 136.547.666 26.5%
1996 199.091.490 31.41%
1997 289.910.431 31.33%
1998 307.775.189 5.8%
1999 298.678.966 -3.05%
2000 332.388.165 10.14%
2001 357.290.577 6.97%
2002 242.096.805 -47.58%
2003 258.410.090 6.31%
2004 278.524.895 7.22%
2005 233.847.256 -19.11%
2006 244.649.577 4.42%
2007 226.041.333 -8.23%
2008 311.275.818 27.38%
2009 366.045.336 14.96%
2010 383.265.987 4.49%
2011 355.226.075 -7.89%
2012 341.017.987 -4.17%
2013 410.084.460 16.84%
2014 445.853.810 8.02%
2015 498.882.491 10.63%
2016 548.044.641 8.97%
2017 1.806.398.388 69.66%
2018 2.177.996.626 17.06%
2019 3.068.876.886 29.03%
2020 3.243.969.209 5.4%
2021 3.519.721.822 7.83%
2022 3.200.862.871 -9.96%
2023 3.090.505.398 -3.57%
2023 2.741.165.147 -12.74%
2024 2.902.617.652 5.56%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Berry Genomics Co.,Ltd Liabilities
Year Liabilities Growth
1994 61.333.484
1995 95.400.185 35.71%
1996 125.145.389 23.77%
1997 104.325.584 -19.96%
1998 96.339.648 -8.29%
1999 77.774.826 -23.87%
2000 125.328.937 37.94%
2001 195.812.159 36%
2002 133.224.410 -46.98%
2003 146.301.471 8.94%
2004 165.774.361 11.75%
2005 135.258.247 -22.56%
2006 144.867.629 6.63%
2007 131.535.963 -10.14%
2008 206.933.922 36.44%
2009 251.535.804 17.73%
2010 261.042.976 3.64%
2011 232.726.536 -12.17%
2012 217.337.616 -7.08%
2013 289.086.709 24.82%
2014 315.825.342 8.47%
2015 381.193.945 17.15%
2016 433.969.037 12.16%
2017 245.935.483 -76.46%
2018 235.675.610 -4.35%
2019 721.830.243 67.35%
2020 821.521.396 12.13%
2021 996.019.770 17.52%
2022 871.535.028 -14.28%
2023 890.967.459 2.18%
2023 846.563.923 -5.25%
2024 995.038.806 14.92%

Berry Genomics Co.,Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.22
Net Income per Share
-0.91
Price to Earning Ratio
-10.29x
Price To Sales Ratio
2.92x
POCF Ratio
22.83
PFCF Ratio
42.59
Price to Book Ratio
1.77
EV to Sales
2.84
EV Over EBITDA
49.54
EV to Operating CashFlow
22.18
EV to FreeCashFlow
41.38
Earnings Yield
-0.1
FreeCashFlow Yield
0.02
Market Cap
3,32 Bil.
Enterprise Value
3,23 Bil.
Graham Number
10.44
Graham NetNet
0.42

Income Statement Metrics

Net Income per Share
-0.91
Income Quality
-0.45
ROE
-0.17
Return On Assets
-0.11
Return On Capital Employed
-0.17
Net Income per EBT
0.96
EBT Per Ebit
1.02
Ebit per Revenue
-0.29
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
-0.01
Gross Profit Margin
0.47
Operating Profit Margin
-0.29
Pretax Profit Margin
-0.3
Net Profit Margin
-0.28

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.04
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.41
Free CashFlow per Share
0.22
Capex to Operating CashFlow
0.46
Capex to Revenue
0.06
Capex to Depreciation
0.58
Return on Invested Capital
-0.15
Return on Tangible Assets
-0.12
Days Sales Outstanding
314.78
Days Payables Outstanding
169.31
Days of Inventory on Hand
124.36
Receivables Turnover
1.16
Payables Turnover
2.16
Inventory Turnover
2.94
Capex per Share
0.19

Balance Sheet

Cash per Share
0,86
Book Value per Share
5,40
Tangible Book Value per Share
5.08
Shareholders Equity per Share
5.3
Interest Debt per Share
0.58
Debt to Equity
0.1
Debt to Assets
0.07
Net Debt to EBITDA
-1.45
Current Ratio
1.59
Tangible Asset Value
1,80 Bil.
Net Current Asset Value
0,52 Bil.
Invested Capital
1562741516
Working Capital
0,56 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,94 Bil.
Average Payables
0,27 Bil.
Average Inventory
204425163
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Berry Genomics Co.,Ltd Dividends
Year Dividends Growth
2001 0

Berry Genomics Co.,Ltd Profile

About Berry Genomics Co.,Ltd

Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and WGS test for genome wide detection of DNA variants, including SNP, CNV, Indel, and SV. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. The company serves various organizations and facilities, including hospitals, research institutions, universities, and corporations. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.

CEO
Dr. Yang Gao
Employee
1.448
Address
Building 5
Beijing,

Berry Genomics Co.,Ltd Executives & BODs

Berry Genomics Co.,Ltd Executives & BODs
# Name Age
1 Ms. Wenlu Ai
Secretary
70
2 Li Gao
Accounting Supervisor
70
3 Mr. Dong Wang
Chief Financial Officer, Deputy GM & Director
70
4 Dr. Yang Gao
GM & Chairman
70
5 Dr. Daixing Zhou
Co-Founder & Chief Scientist
70

Berry Genomics Co.,Ltd Competitors